With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

The global obesity epidemic has spurred pharmaceutical companies to invest heavily in developing effective weight management solutions, leading to a surge in clinical trials for anti-obesity ...

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

Novo Nordisk'sNVO oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday. Novo Nordisk stock jumped on the news. In comparison, Eli Lilly'sLLY weight-loss shot ...

Lilly's Zepbound surpasses Wegovy in dollar sales, while pricing cuts and copycats pressure Novo's growth outlook.

Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by ...

In coming weeks, Wegovy pill will be available in four doses: a starter dose of 1.5 mg, as well as 4 mg, 9 mg, and 25 mg. As with injectable Wegovy, most patients will start with the lowest dose and ...

A few months into GLP-1 treatment, many patients encounter an unexpected and distressing side effect: significant hair loss.

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...